美迪西(688202) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥451,400,695.33, representing a year-on-year increase of 26.80%[5] - The net profit attributable to shareholders for the same period was ¥101,568,576.29, reflecting a growth of 31.58% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,677,712.67, with a year-on-year increase of 32.06%[5] - Basic earnings per share for Q1 2023 were ¥1.17, up by 31.46% year-on-year[6] - Total revenue for Q1 2023 reached RMB 451.4 million, a 27% increase from RMB 356.0 million in Q1 2022[19] - Operating profit for Q1 2023 was RMB 114.9 million, up 29% from RMB 88.9 million in Q1 2022[20] - Net profit for Q1 2023 was RMB 101.6 million, representing a 31% increase compared to RMB 77.2 million in Q1 2022[20] - Basic and diluted earnings per share for Q1 2023 were both RMB 1.17, compared to RMB 0.89 in Q1 2022[21] Research and Development - The total R&D investment amounted to ¥28,370,481.60, accounting for 6.28% of operating revenue, a decrease of 0.30 percentage points from the previous year[6] - Research and development expenses for Q1 2023 totaled RMB 28.4 million, an increase of 21% from RMB 23.4 million in Q1 2022[19] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,468,249,929.75, an increase of 5.95% from the end of the previous year[6] - The company's current assets totaled RMB 1,178,798,922.61, up from RMB 1,072,633,100.49 at the end of 2022, indicating an increase of about 10%[14] - Accounts receivable increased significantly to RMB 673,484,506.18 from RMB 513,457,205.12, reflecting a growth of approximately 31%[14] - The company's cash and cash equivalents decreased to RMB 143,624,077.08 from RMB 197,133,665.75, a decline of about 27%[14] - Total liabilities rose to RMB 763,395,322.04 from RMB 726,796,211.73, marking an increase of around 5%[16] - The company's equity attributable to shareholders increased to RMB 1,704,854,607.71 from RMB 1,602,784,731.03, representing a growth of approximately 6%[16] - The company reported a decrease in inventory, which stood at RMB 170,605,554.76 compared to RMB 171,124,090.16 at the end of 2022, a slight decline of about 0.3%[14] - The company’s long-term equity investments slightly increased to RMB 10,162,761.58 from RMB 10,142,728.36, showing a marginal growth of about 0.2%[15] - The company’s short-term borrowings increased to RMB 289,170,242.99 from RMB 229,413,798.58, reflecting a rise of approximately 26%[15] - The company’s total non-current liabilities decreased to RMB 99,548,826.54 from RMB 109,753,887.96, indicating a reduction of about 9%[16] Cash Flow - The net cash flow from operating activities was -¥17,443,008.18, primarily due to reduced payments for experimental animals and increased tax refunds received[9] - Cash flow from operating activities showed a net outflow of RMB 17.4 million, an improvement from a net outflow of RMB 51.0 million in Q1 2022[23] - Cash and cash equivalents at the end of Q1 2023 were RMB 142.5 million, down from RMB 204.8 million at the end of Q1 2022[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,766[11] - The top shareholder, Chen Jinzhan, holds 15.64% of the shares, totaling 13,611,623 shares[11] Other Financial Metrics - The weighted average return on equity was 6.14%, an increase of 0.49 percentage points[6] - The company reported a tax expense of RMB 13.1 million for Q1 2023, compared to RMB 11.1 million in Q1 2022[20] - The company experienced a foreign exchange loss of RMB 770,934.14 in Q1 2023, compared to a loss of RMB 421,440.63 in Q1 2022[23]